SCHEDULE: Empery Asset Management Discloses 8.83% Stake in Immuneering
Beneficial Ownership Report
Empery Asset Management, LP and its managing members reported a beneficial ownership of 8.83% of Immuneering Corp.'s Class A Common Stock.
Summary
- Empery Asset Management, LP, along with Ryan M. Lane and Martin D. Hoe, collectively reported beneficial ownership of 5,188,755 shares of Immuneering Corp.'s Class A Common Stock.
- This ownership represents 8.83% of the company's Class A Common Stock.
- The reported shares include 1,077,764 shares issuable upon the exercise of warrants.
- The percentage is calculated based on 57,655,779 shares of Common Stock outstanding as of September 24, 2025.
- The acquisition was made in the ordinary course of business and not for the purpose of changing or influencing control of Immuneering Corp.
Sentiment
Score: 7
Explanation: The filing indicates a significant institutional investment in Immuneering Corp., which is generally viewed positively as a vote of confidence from a sophisticated investor. While not a performance report, it suggests a favorable view of the company's prospects by the reporting entity.
Positives
- A significant institutional investor, Empery Asset Management, LP, has taken an 8.83% stake in Immuneering Corp., potentially signaling confidence in the company's future.
- The stake includes common stock and warrants, indicating a long-term or strategic interest.
Industry Context
The disclosure of a significant institutional stake by Empery Asset Management in Immuneering Corp., a biotechnology company, highlights continued investor interest in the life sciences sector. Such investments can be seen as a vote of confidence in a company's pipeline or market position within the competitive biotech landscape.
Stakeholder Impact
- Shareholders: Existing shareholders may view the significant institutional investment as a positive signal, potentially increasing confidence and demand for the stock.
- Management: The investment could be seen as validation of the company's strategy and potential, potentially influencing future strategic decisions.
Key Dates
| Date | Description |
|---|---|
| 2025-09-24 | Date used for calculating outstanding shares (57,655,779) as reported in the Company's Prospectus Supplement. |
| 2025-09-30 | Date of event requiring the filing of this statement. |
| 2025-10-21 | Date of signing and filing of the Schedule 13G statement. |
Keywords
Immuneering Corp, Empery Asset Management, Class A Common Stock, Schedule 13G, Beneficial Ownership, Institutional Investor, Warrants, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.